Table 3 Evening pre-dose FEV1 on Day 28 of treatment and improvement from period baseline for each treatment regimen (all placebo treatments were pooled for these analyses)
From: Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
Placebo | FF 200 μg OD | FF 100 μg BD | FP 200 μg OD | FP 100 μg BD | |
|---|---|---|---|---|---|
Number of patients | 187 | 140 | 142 | 42 | 43 |
LS mean, ml (SE) | 2605 (43.4) | 2714 (44.4) | 2703 (44.3) | 2693 (53.5) | 2737 (53.3) |
LS mean change from period baseline, ml (SE) | 112 (18.6) | 221 (20.9) | 210 (20.7) | 199 (36.5) | 244 (36.1) |
LS mean difference (active-placebo), ml (95% CI) | NA | 108 (64-153); p < 0.001 | 98 (54-142); p < 0.001 | 87 (14-161); p = 0.020 | 132 (59-205); p < 0.001 |
LS mean difference (FF 200 μg OD-FF 100 μg BD), ml (95% CI) | NA | 11 (-35-56); p = 0.641 | NA | NA | NA |